Mediators of Atherosclerosis in South Asians Living in America
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Sep 21, 2010
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Mediators of Atherosclerosis in South Asians Living in America" is studying why South Asian individuals, including those from India, Pakistan, Bangladesh, Nepal, and Sri Lanka, have higher rates of heart disease compared to other groups. Researchers want to find out the specific risk factors that contribute to this issue, particularly looking at early signs of atherosclerosis, which is a condition where arteries become narrow and can lead to heart attacks and strokes. This study will take place at three centers in the United States and will help us understand how the causes of heart disease in South Asians differ from those in other ethnic groups.
To participate in this study, individuals need to be between 40 and 84 years old and have South Asian ancestry, meaning at least three of their grandparents were born in one of the countries mentioned. However, people with certain health conditions, like a history of heart attacks or strokes, or those who are currently being treated for cancer, cannot join. Participants in the study will be asked to attend regular visits and provide information that will help researchers gather valuable data about heart health in the South Asian community. This research is important because it aims to improve our understanding of cardiovascular diseases in a population that has not been deeply studied before.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • South Asian ancestry defined by having at least 3 grandparents born in one of the following countries: India, Pakistan, Bangladesh, Nepal, or Sri Lanka
- • age between 40 and 84 years.
- Exclusion Criteria:
- • Physician diagnosed heart attack, stroke or transient ischemic attack (TIA), heart failure, or angina (or use of nitroglycerin)
- • Current atrial fibrillation
- • Past history of cardiovascular procedures (coronary artery bypass graft (CABG) Surgery, angioplasty, valve replacement, pacemaker or defibrillator implantation, or any surgery on the heart or arteries)
- • Active treatment for cancer
- • Life expectancy less than 5 years due to serious medical illness
- • Impaired cognitive ability as judged by the reviewer
- • Plans to move out of the study region in next 5 years
- • Weight greater than 300 pounds
- • Living in a nursing home or on a waiting list
- • Unable to speak/read/write English, Hindi, Urdu, or Bangla
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Chicago, Illinois, United States
San Francisco, California, United States
Patients applied
Trial Officials
Alka Kanaya, MD
Principal Investigator
University of California, San Francisco
Namratha Kandula, MD
Principal Investigator
Northwestern University
Nadia Islam, PhD
Principal Investigator
New York University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials